Skip to main content

Table 1 Patient demographics and baseline characteristics, based on CID using D1 and D2

From: One‐year clinically important deterioration and long‐term clinical course in Japanese patients with COPD: a multicenter observational cohort study

  All patients CID1 + group CID1 − group P-value CID2 + group CID2 − group P-value
(n = 259) (n = 152) (n = 107) (n = 97) (n = 162)
Demographics
Age, years 69.6 ± 7.8 69.8 ± 7.5 69.4 ± 8.2 0.74 70.1 ± 7.2 69.4 ± 8.1 0.45
Female, N (%) 15 (5.8%) 7 (4.6%) 8 (7.5%) 0.42 4 (4.1%) 11 (6.8%) 0.43
Body mass index, kg/m2 22.2 ± 3.2 22.1 ± 3.3 22.5 ± 3.2 0.30 22.0 ± 3.2 22.4 ± 3.3 0.33
Current smoker, N (%) 73 (28.2%) 39 (25.7%) 34 (31.8%) 0.33 21 (21.7%) 52 (32.1%) 0.09
Pack-years 56.0 (43.0–78.0) 56.0 (43.0–75.8) 57.0 (43.0–79.5) 0.66 55.0 (42.0–73.5) 56.6 (43.5–82.0) 0.33
Pulmonary function test
Post-BD FEV1, L 1.7 ± 0.7 1.7 ± 0.7 1.8 ± 0.7 0.19 1.6 ± 0.6 1.8 ± 0.7 0.01
Post-BD FEV1, % predicted 64.5 ± 21.9 62.3 ± 21.8 67.8 ± 21.6 0.05 59.2 ± 20.9 67.8 ± 21.9 0.002
Post-BD FEV1/FVC, % 51.1 ± 12.5 49.6 ± 12.6 53.2 ± 12.1 0.02 48.2 ± 12.7 52.8 ± 12.2 0.003
DLco, % predicted 78.1 ± 25.0 76.2 ± 24.8 80.7 ± 25.2 0.16 77.3 ± 24.8 78.5 ± 25.2 0.70
Kco, % predicted 63.8 ± 24.3 62.6 ± 24.7 65.4 ± 23.7 0.37 63.3 ± 24.6 64.0 ± 24.2 0.82
Patient-reported outcomes
Chronic bronchitis, N (%) 29 (11.2%) 16 (10.5%) 13 (12.2%) 0.69 13 (13.4%) 16 (9.9%) 0.42
mMRC dyspnea scale ≥ 2, N (%) 137 (52.9%) 84 (55.3%) 53 (49.5%) 0.38 55 (56.7%) 82 (50.6%) 0.37
SGRQ total score 31.8 ± 17.4 32.4 ± 17.4 31.1 ± 17.4 0.57 33.8 ± 17.3 30.7 ± 17.3 0.16
CT emphysema score 1.2 (0.7–2.0) 1.2 (0.8–2.2) 1.1 (0.6–2.0) 0.30 1.2 (0.7–2.0) 1.2 (0.7–2.2) 0.97
Comorbidities
Any cardiovascular disease 58 (22.4%) 33 (21.7%) 25 (23.4%) 0.76 23 (23.7%) 35 (21.6%) 0.76
Ischemic heart disease 18 (7.0%) 10 (6.6%) 8 (7.5%) 0.81 6 (6.2%) 12 (7.4%) 0.80
Diabetes 12 (4.6%) 4 (2.6%) 8 (7.5%) 0.08 3 (3.1%) 9 (5.6%) 0.54